27 studies on Mazdutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 147 published Mazdutide COA source records from third-party laboratories, covering 68 publicly attributable vendor identities. Across 130 records with positive numeric purity, the arithmetic mean is 99.38%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 13 records report measured amount more than 10% below the label. The latest recorded test date is 2026-09-28. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-09-28. Aggregate calculated: 2026-10-18T04:27:18.974579+00:00. Calculation time is not a laboratory observation date.
Within that total, 26 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 9 | 99.54% | 0 of 9 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 6 | 99.43% | 0 of 6 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 6 | 99.41% | 0 of 6 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #115352 (99.48%) · #110526 (99.98%) · #107347 (99.64%) · #107346 (99.27%) · #105220 (99.61%) · #117971
If successful, this trial could establish **Mazdutide** as a novel and effective pharmacological strategy for **prediabetes reversal**, offering a significant advancement beyond current lifestyle-focused interventions…
If successful, this trial could establish **mazdutide** as a novel therapeutic strategy for directly mitigating **coronary atherosclerosis** progression in patients with **overweight** or **obesity**, beyond its known…
A study investigates the efficacy and safety of adjuvant GLP-1 receptor agonist therapy combined with bariatric surgery in Chinese patients with obesity.
**Mazdutide 9mg** demonstrates a potent new therapeutic option for **obesity** management, particularly relevant for Chinese adults. The substantial **16.65%** mean weight loss and high responder rate (over **84%** ac…
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
The GLORY-1 study successfully completed its 48-week double-blind treatment period, evaluating the efficacy and safety profiles of IBI362 at two distinct doses against placebo. While specific numerical results regardi…
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The successful completion of this Phase 1 trial is a significant step towards developing a potential new treatment for adolescent obesity. Given the rising prevalence of obesity in young populations and the limited th…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
This research provides a crucial molecular link between exercise and its anti-aging benefits, identifying betaine as a key mediator. The finding that betaine acts as a 'beneficial mimetic' for long-term exercise is pa…
The successful completion of this Phase 1 study is a critical milestone, as it provides the foundational safety and pharmacokinetic data necessary for advancing LY3305677 into further clinical development. Understandi…
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The development of HDM1005 represents a potential new therapeutic avenue for patients with T2DM who struggle with current treatment regimens. If HDM1005 demonstrates superior efficacy or a better safety profile compar…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
The successful completion of this early-phase trial is a significant step forward for IBI362, a novel therapeutic candidate for Type 2 Diabetes. This foundational data on its human safety, tolerability, and drug profi…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
This case report provides crucial preliminary evidence supporting the potential of Mazdutide as a comprehensive treatment option for adolescents grappling with the complex interplay of obesity, type 2 diabetes, and hy…
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
PCOS is a complex condition with significant unmet medical needs, particularly for obese patients struggling with hyperandrogenism and metabolic dysfunction. If Mazdutide proves effective in reducing FAI, it could rep…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
Free, no account — handy when you're working with Mazdutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account